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S100A8/A9 and S100A9 reduce acute lung injury
Yuka Hiroshima1, Kenneth Hsu, Nicodemus Tedla, Sze Wing Wong, Sharron Chow, Naomi Kawaguchi2 and
Carolyn L Geczy
S100A8 and S100A9 are myeloid cell-derived proteins that are elevated in several types of inflammatory lung disorders.
Pro- and anti-inflammatory properties are reported and these proteins are proposed to activate TLR4. S100A8 and S100A9 can
function separately, likely through distinct receptors but a systematic comparison of their effects in vivo are limited. Here we
assess inflammation in murine lung following S100A9 and S100A8/A9 inhalation. Unlike S100A8, S100A9 promoted mild
neutrophil and lymphocyte influx, possibly mediated in part, by increased mast cell degranulation and selective upregulation of
some chemokine genes, particularly CXCL-10. S100 proteins did not significantly induce proinflammatory mediators including
TNF-α, interleukin-1β (IL-1β), IL-6 or serum amyloid A3 (SAA3). In contrast to S100A8, neither preparation induced S100A8 or
IL-10 mRNA/protein in airway epithelial cells, or in tracheal epithelial cells in vitro. Like S100A8, S100A9 and S100A8/A9
reduced neutrophil influx in acute lung injury provoked by lipopolysaccharide (LPS) challenge but were somewhat less inhibitory,
possibly because of differential effects on expression of some chemokines, IL-1β, SAA3 and IL-10. Novel common pathways
including increased induction of an NAD+-dependent protein deacetylase sirtuin-1 that may reduce NF-κΒ signalling, and
increased STAT3 activation may reduce LPS activation. Results suggest a role for these proteins in normal homeostasis and
protective mechanisms in the lung.
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S100A8 and S100A9 (also known as MRP8 and MRP14) are found in
lungs of patients with airway inflammation including cystic fibrosis,
asthma, acute respiratory distress disorder and chronic obstructive
pulmonary disease (reviewed in ref. 1). These proteins are constitutively
expressed in high amounts in neutrophils, and the S100A8/A9 hetero-
complex (known as calprotectin) is the proposed functional form in
lesions associated with neutrophil influx,2 displaying antimicrobial
activities against a variety of micro-organisms.3 Although less well
studied, the individual proteins can also be elevated and can act
independently.2,4 In keeping with this, and unlike S100A9,5 gene
deletion of S100A8 is embryonic lethal6 and S100A8 is induced in the
absence of S100A9 in several cell types.3 S100A9/ mice have been
used to explore S100A8 and S100A9 functions in models of inflamma-
tion. These are apparently normal, although neutrophil concentrations
of S100A8 are also reduced and these cells are less responsive to some
chemoattractants.5,7 S100A9/ mice were protected from endotoxin
challenge and E. coli-induced abdominal sepsis,8 and S100A8 and
S100A9 were suggested to contribute to injury by potentiating
lipopolysaccharide (LPS) responses via TLR4 ligation. Despite this,
and/or promotion of inflammation via the receptor for advanced
glycation end products (RAGE) by S100A8 and S100A9,9 we recently
defined protective functions of S100A8 in acute murine asthma10 and
LPS-induced acute lung injury (ALI).11 In part, this is because S100A8
efficiently scavenges oxidants that modulate signalling pathways
involved in mast cell activation and promotes interleukin-10 (IL-10)
induction in airway epithelial cells. S100A9 is a less efficient oxidant
scavenger.12
S100A8 and S100A9 functions may depend on structural features
including the extent of complex formation (for example, tetramer
versus monomer), divalent cation binding, amino acid sequence
differences and post-translational modifications.12,13 They preferen-
tially form non-covalent heteromeric, rather than covalent complexes,
even when treated with strong oxidants such as HOCl.12 In addition,
the C-terminal domain of S100A9, termed neutrophil-immobilising
factor, is structurally divergent, and downregulates leucocyte adhesion,
reduces macrophage spreading and phagocytosis.14 Moreover, there is
emerging evidence that these proteins likely interact with distinct
receptors. S100A9 binds members of the immunoglobulin receptor
family including basigin (CD147 or EMMPRIN)15 and CD85j
(LILRB1).16 Ligation of LILRB1 by S100A9, but not S100A8,
stimulates anti-HIV activity of natural killer cells. These proteins also
bind heparin and carboxylated N-glycans with different affinities and
interaction with the latter on glycated RAGE, CD36 (reviewed in
ref. 13), and the immunoglobulin-like receptors, is proposed. S100A9
also contributes to the anti-tumour activity of myeloid-derived
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suppressor cells but functions of S100A8 in this context are unclear.17
Extracellularly, S100A8 and S100A9 are traditionally considered
proinflammatory although functions in lung inflammation are
controversial. Tumour necrosis factor-α (TNF-α) induction was
proposed to initiate inflammation following intratracheal S100A9
delivery to normal mice18 although intranasal delivery using an
adenoviral vector failed to do so.19 The latter predominantly promoted
a macrophage influx 8 days post-challenge in a response independent
of the two putative receptors: TLR4 and RAGE.19 More recently,
unexpected protective effects of S100A9 and S100A8/A920,21 were
reported, and in humans with sepsis, delayed overexpression of
S100A9 is associated with occurrence of secondary hospital-acquired
infections, again implying protective effects.22 Consistent with this,
S100A9 maintains circulating neutrophil numbers and recruitment to
Strep pneumonia-infected murine lungs, principally by regulating
G-CSF production21 and S100A9-deficiency is associated with
increased cytokine levels and aggravated lung pathology in mice
infected with S. aureus.20
Our studies indicate a role for S100A8 in immunoprotection and/or
resolution of inflammation.10,11 Unlike S100A8, S100A9 is not
induced in murine macrophages by TLR agonists;3 S100A8, induction
is IL-10-dependent, regulated in a manner similar to the IL-10
gene and enhanced by corticosteroids, responses uncharacteristic of
TLR agonists. Importantly, S100A8 inhalation inhibited ALI in
a manner similar to dexamethasone, and may contribute to immu-
nosuppressive functions of corticosteroids.11 Together with the
differences in their structure, potential post-translational modifications
and putative receptors, we proposed that S100A9 may promote
different responses to S100A8 in murine lung. Here we present
a systematic comparative study of the functional effects of S100A9
and S100A8/A9 inhalation in normal lung and propose distinct
modulatory roles.
Unlike S100A8,11 S100A9 and S100A8/A9 inhalation directly
promoted mild neutrophil influx, possibly mediated in part by
increased mast cell (MC) degranulation and differential upregulation
of particular chemokine genes. Unlike LPS, low or high dose intranasal
S100A9 did not induce significant amounts of TNF-α or CCL-2.
CXCL-10 was only elevated by S100A9. Neutrophil influx in response
to LPS inhalation was suppressed by S100A9 and S100A8/A9 although
there were differential effects on expression of some chemokine genes,
IL-1β and the acute phase reactant serum amyloid A3 (SAA3), which
promotes lung neutrophilia,23 only S100A8 significantly suppressed
SAA3 in ALI. In marked contrast to S100A8, neither S100A9 nor
the complex induced IL-10 in the airways, or in tracheal epithelial
cells in vitro. Characterisation of the receptors for these S100 proteins
in lung would likely reveal novel mechanisms that modulate
complementary immunoregulatory roles of S100A8, S100A9 and
S100A8/A9.
RESULTS
The model used here was one commonly employed to study
LPS-induced lung injury. Because they are reported TLR4 agonists,
we first examined effects of inhalation of S100A9 and S100A8/A9 in
lungs from naïve mice. When doses of S100A9 were tested, 10 μg was
chosen for studies over a time course (1–12 h), so that we could
capture mediator production at early and later stages, and could be
compared with results published for a similar dose of S100A8.11
The ability of these proteins to modulate inflammation induced
by LPS challenge was tested by administering 10 μg intranasally
2 h before LPS inhalation, and lungs harvested 4 h later, a time point
when LPS-induced genes are highly expressed.
S100A9 and S100A8/A9 promote neutrophil and lymphocyte
recruitment in naïve lung
Total leucocyte numbers in BALF from control (Hanks balanced salt
solution (HBSS)-treated) mice were constant over 20 h. Lymphocytes
(~0.5–1% total leucocytes) were elevated 2–3.3-fold by S100A9 at
1, 4, 6 and 12 h post-inhalation (Figure 1a) and at 1 and 4 h were
similar to lymphocyte numbers elicited by LPS alone (2.4± 0.5 and
3.4± 0.4 × 104; n= 7, respectively). Neutrophils were rare in
bronchiolar lavage fluid (BALF) from HBSS-treated mice. In compar-
ison, significant neutrophil infiltration was evident 4 h post S100A9-
inhalation even though numbers were low (2.7–3.1× 104) and
decreased gradually over 12 h, with a second peak at 20 h
(Figure 1b). In contrast, BALF harvested 4 h post LPS-treatment
contained some 10–15-fold more neutrophils (55.3± 11.0× 104;
n= 7). S100A8/A9 promoted similar lymphocyte and neutrophil
recruitment although numbers were somewhat less than seen with
S100A9 6–20 h post-inhalation (Figures 1a and b). Similar to
S100A8,11 infiltration of S100-positive myeloid cells within lung tissue
was negligible 1 or 4 h post S100A9 inhalation whereas S100A8/A9
caused a mild influx of S100A9-positive/S100A8-negative myeloid cells
within the extravascular compartment, and S100A9 deposits were
obvious on the extracellular matrix (Figure 1c).
Expression of genes that may modulate leucocyte recruitment in
lung post S100 or LPS administration, relative to HBSS control, are
shown in Supplementary Tables 1 and 2 respectively. LPS significantly
increased most chemokine genes including CCL-2 (27-fold), CXCL-1
(34-fold), CXCL-2 (90-fold), CXCL-9 (23.6-fold) and CXCL-10
(231-fold). In contrast, S100A9 stimulated low but significant
increases in some chemokine genes (CCL-3, 4, CXCL-1, 2, 9
and 10) within an hour; except for CXCL-10, messenger RNAs
(mRNAs) declined, whereas CXCL-10 mRNA was some 30.9-fold
above controls at 12 h. CXCL-10 concentrations in BALF harvested
4 h post S100A9 inhalation increased from 30.8± 9.3 pg ml− 1 at
baseline, to 102.7± 7.0 pg ml− 1 (Po0.001; Figure 1d) but receded
thereafter. In contrast, and in keeping with mRNA expression,
CXCL-10 concentrations in BALF from mice treated with S100A8/
A9 were not significantly different from controls. Similar to S100A9,
S100A8/A9 increased CXCL-1 and CXCL-2 mRNAs 6–10-fold after
1 h. Unlike LPS, CCL-2 mRNA was not significantly elevated.
SAA is proinflammatory24 and promotes neutrophilic infiltration
in the lung.23 In marked contrast to its very strong induction by
LPS alone (Supplementary Table 2), endogenous SAA3 mRNA was
reduced by both S100 preparations (Supplementary Table 1) and the
negative response to S100A9 was sustained over 12 h. ICAM-1
mediates neutrophil adhesion; unlike S100A8/A9, S100A9 significantly
increased ICAM-1 mRNA 12 h post inhalation (24.6-fold above
control), and may facilitate the later elevated neutrophil influx seen
at 20 h (Figure 1b). Matrix metalloproteases (MMP) influence
leucocyte transmigration and are modulated by S100A8/A9 in some
cells.25 Supplementary Table 1 shows that S100A9 increased MMP-2
mRNA 2.8–3.5-fold over 1–12 h whereas induction by S100A8/A9 was
low, and delayed (4–6 h). Induction of MMP-9 mRNA by S100A9
(5.4-fold increase) and S100A8/A9 (3.7-fold) was rapid but decreased
1 h post inhalation. However immunohistochemistry failed to detect
MMP-9 in lung specimens from any sample set harvested over 1–20 h.
Differential effects of S100s on pro- and anti-inflammatory genes in
naïve lung
S100A9 and S100A8/A9 marginally increased TNF-α mRNA 1 h post
challenge (Supplementary Table 1); no significant increases were
found at later time points. BALF harvested 1–20 h post inhalation of
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the S100 preparations did not contain significantly elevated TNF-α
above concentrations in control BALF (3.2± 0.2 pg ml− 1 (lower limits
of assay); n= 4/group, Po0.05). Moreover TNF-α concentrations in
BALF from mice treated with 1, 10 or 25 μg S100A9 were similar, and
not significantly greater than control concentrations (Supplementary
Table 3). This contrasts markedly with the increased gene expression
(Supplementary Table 2) and high amounts of TNF-α induced by
LPS (684.8± 124.5 pg ml− 1; Table 1).
Changes in IL-1β mRNA were also slight; BALF from mice treated
with S100A8/A9 or S100A9 harvested at 12 h contained 7.7± 1.4 and
8.0± 1.0 pg ml− 1 respectively, some threefold more than in BALF
from mice treated with HBSS (2.3± 1.1 pg ml− 1; n= 4, Po0.05).
Interestingly, at 1 h post-S100A9 inhalation, basal expression of the
IL-1 receptor antagonist (IL-1RA) gene was significantly reduced
by 50-fold; S100A8/A9 caused a 6.7-fold decrease that was only
obvious in lung samples harvested at 4–6 h (Supplementary Table 1).
Only S100A8/A9 induced low and transient IL-6 mRNA expression
1 h post-inhalation but amounts in BALF were similar to controls.
In our hands, we detected little direct induction of these cytokines
following in vitro incubation of tracheal epithelial cells, the human
epithelial cell line A549, or murine elicited macrophages, murine/
human monocytes or monocyte-derived macrophages, or various
monocyte/macrophage cell lines stimulated using the appropriate
murine or human S100 proteins over a dose range (0–10 μg ml− 1
for most experiments).
S100A9 inhalation increased IFN-γ mRNA over 12 h by 17.3-fold
whereas S100A8/A9 caused a transient increase 4–6 h post inhalation
(Supplementary Table 1). However quantities in BALF from S100A9-
treated mice were very low (2.3± 0.5 pg ml− 1) and at other time
points, below the level of detection (1.95 pg ml− 1).
We next examined IL-10 mRNA in lung tissue over 1–20 h.
Compared to the 1183-fold increase induced at 12 h by S100A8,11
S100A8/A9 or S100A9 did not significantly alter basal IL-10 mRNA
over the time course (Supplementary Table 1), and different S100A9
Figure 1 S100A9 promotes neutrophil recruitment and CXCL-10 production. Total numbers of (a) lymphocytes and (b) neutrophils in BALF from control
(HBSS), S100A9 or S100A8/A9-treated mice (both 10 μg; harvested 1, 4, 6, 12 and 20 h post inhalation). (c) Anti-S100A8 and -S100A9
immunoreactivities of lung sections from mice harvested 1, 4 or 12 h post S100A9 or S100A8/A9 inhalation. Sections are representative of 4 mice per
group; scale bars, 50 μm. S100A9-positive airway lining cells are indicated with arrows. (d) CXCL-10 in BALF from mice treated with S100A9 or S100A8/A9
(1, 4, 6 and 12 h post inhalation). Data are means± s.e.m., n=4 mice/group; *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001 compared with
HBSS-treated mice.
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doses had no effect on IL-10 concentrations in BALF (Supplementary
Table 3). Immunohistochemistry detected little IL-10 in lungs from
S100A9-treated mice (Supplementary Figure 1), contrasting markedly
with the high IL-10 expression seen in airway epithelial cells 12 h post
S100A8 inhalation.11
S100A9 or S100A8/A9 inhalation had little effect on S100A8mRNA;
low S100A9mRNA induction occurred 12 h post inhalation of S100A9
and 1 h post inhalation of S100A8/A9 (Supplementary Table 1).
Screening of lung sections (n= 4/group) indicated little S100 expres-
sion in airway epithelial cells 1, 4 or 12 h post-S100A9 inhalation.
Low S100A8 and S100A9 reactivity was obvious in infiltrating myeloid
cells after 1–4 h, with S100A9 expression in airway epithelial cells
becoming more prominent 12 h post S100A8/A9 challenge
(Figure 1c). No S100A8 or S100A9 was seen in lungs from mice
20 h after any S100 treatment (not shown).
S100 modulation of leucocyte recruitment in acute lung injury
Neutrophil numbers in BALF 1 h post LPS inhalation were not
significantly elevated, so the 4 h time point, when ~ 55.3± 11.0× 104
were elicited, was used for analysis. S100A9 and S100A8/A9
significantly reduced neutrophil numbers (Figure 2a). Immunohisto-
chemistry confirmed S100A9-positive myeloid cells with neutrophil
morphology in lungs 4 h post LPS and these appeared reduced in
S100 pretreated lungs (Figure 2b). Lymphocyte numbers in BALF
from the LPS (3.5± 0.4 × 104; n= 7) and S100A9 pretreatment+LPS
groups were similar (3.1± 0.5 × 104; n= 5).
MC are essential for responses to endotoxin in vivo and perivascular
MC degranulation promotes neutrophil exit from the lumen
(reviewed in ref. 26). S100A8 inhibits MC activation,10,11 but here
we found that S100A8/A9 and S100A9 pretreatment significantly
potentiated MC degranulation provoked by LPS, increasing
β-hexosaminidase (β-hex) levels some 3–4-fold (Figure 2c). Although
MC numbers in lungs of BALB/c mice are low, when intact and
degranulating MC were counted, ratios of degranulating cells were
elevated in all samples compared with HBSS+phosphate-buffered
saline (PBS)-treated mice (Figure 2d). Because we found little direct
effect of S100A9 on MC activation in vitro (unpublished observations),
to investigate this further, we tested whether S100 inhalation in
naïve mice might activate MC in vivo. S100A9 significantly increased
β-hex in BALF harvested 1 and 4 h post inhalation and S100A8/A9
tended to do so (Figure 2e). IL-33 activates MCs27 and interestingly,
IL-33 mRNA significantly increased 1.8-fold 1 h post S100A9
inhalation (Supplementary Table 1).
S100A8/A9 and S100A9 reduce acute lung injury in response to LPS
Expression of mRNAs encoding inflammatory genes was generally
low in lungs from mice harvested 1 h post LPS inhalation
(for example, CCL-2: 4.3-fold, CXCL-10: 5.8-fold above control),
compared to the high expression, particularly of chemokine genes, at
4 h (CCL-2: 27-fold, CXCL-10: 231-fold above control values), so this
time point was chosen for most analyses. Supplementary Table 2
and the heat map shown in Figure 3a compare chemokine
and cytokine/proinflammatory gene expression in S100 or HBSS
(control)-pretreated lungs challenged 2 h later with LPS. The volcano
plot (Figure 3b) shows that several cytokine and chemokine genes
were significantly reduced by 42.5-fold (P= 0.05) in LPS-challenged
lungs from mice pretreated with S100A9 compared to control (HBSS);
no genes were significantly upregulated by S100A9. S100A9 pretreat-
ment reduced TNF-α mRNA expression in lungs of LPS-challenged
mice (Figure 3b) from 14.2-fold to 3-fold above baseline. TNF-α in
BALF was also significantly less (164.4 ± 105.2 pg ml− 1 compared to
684.8± 124.5 with LPS alone; Table 1). Moreover, inhalation of 1 or
10 μg S100A9 suppressed TNF-α induction by LPS to the same extent,
suggesting high potency; the high dose (25 μg) was also significantly
suppressive (Supplementary Table 4). S100A8/A9 similarly reduced
TNF-α mRNA and concentrations in BALF. IL-6 mRNA was some
fivefold less in lungs of mice pretreated with S100A9, and twofold less
with S100A8/A9 compared to LPS alone (Supplementary Table 2).
These changes were reflected by IL-6 concentrations in BALF
(5.1± 4.4 and 36.6± 10.6 pg ml− 1 respectively, compared to
88.7± 22 pg ml− 1 with LPS alone; Table 1). IL-1β mRNA induction
by LPS was reduced from ~8 to ~ 4-fold by S100A9 and IL-1β
concentrations in BALF were ~ 50% less than in BALF from mice
challenged with LPS alone; S100A8/A9 had no significant effect
(Supplementary Table 2 and Table 1). S100A9 inhalation also
significantly reduced mRNA induction of IL-1RA, CSF2, and
MMP13 by LPS whereas S100A8/A9 had little effect (Figure 3c).
The low amounts of IL-10 induced by LPS were reduced to
approximately the same extent by 1-25 μg S100A9 (Supplementary
Table 4).
Most chemokine genes induced by LPS were markedly suppressed
by S100A9; S100A8/A9 was somewhat less effective (Figure 3 and
Supplementary Table 2). For example, the 231-fold upregulation of
CXCL-10 mRNA by LPS remained at baseline in lungs from mice
pretreated with S100A9, but were fourfold above baseline values with
S100A8/A9. Similarly, CCL-2 mRNA increased ~ 27-fold following
LPS inhalation; S100A9 pretreatment suppressed induction to almost
background whereas in lungs from S100A8/A9-treated mice,
CCL-2 mRNA expression was only 2.4-fold less than with LPS alone.
CCL-2 and CXCL-10 concentrations in BALF were less in
S100A9-, than in S100A8/A9-pretreated mice, compared to LPS alone
(Table 1); 1, 10 or 25 μg S100A9 were all suppressive (Supplementary
Table 4). We next tested whether tracheal epithelial cells were
S100-responsive in vitro and included S100A8 as this had not been
tested. No S100 preparation directly induced significant chemokine
gene expression whereas LPS increased CCL-2 and CXCL-10 mRNAs
some 6- and 36-fold, respectively (Figures 4a and b). Although S100A9
was somewhat suppressive, S100A8/A9 and S100A8 significantly
reduced CCL-2 mRNA induction by LPS to about the same extent.
CXCL-10 mRNAs were reduced by all preparations but only S100A8
was significantly suppressive (by 69%; Figure 4b).
The high SAA3 mRNA induced by intranasal LPS (419-fold
above basal expression) was reduced to 85-fold by S100A9
whereas S100A8/A9 inhalation was ineffective (Supplementary
Table 2). In keeping with this, SAA3 was significantly above
Table 1 S100A9 or S100A8/A9 effects on SAA3 and mediator
concentrations in BALF induced by LPS
HBSS+PBS HBSS+LPS S100A9+LPS S100A8/A9+LPS
SAA3 13.6±0.8** 31.9±3.0 27.2±5.2 34.6±3.2
TNF-α 26.6±8.1*** 684.8±124.5 164.4±105.2** 159.3±46.3**
IL-1β 6.6±2.5 25.2±3.9 13.6±2.7 38.4±7.3
IL-6 2.0±1.3** 88.7±22.0 5.1±4.4** 36.6±10.6
CCL-2 3.6±1.6* 23.5±7.7 6.0±1.2 11.4±1.1
CXCL-10 45.2±19.5 200.0±77.5 9.9±3.7* 97.1±16.6
Abbreviations: HBSS, Hanks balanced salt solution; IL, interleukin; LPS, lipopolysaccharide;
PBS, phosphate-buffered saline; SAA3, serum amyloid A3; TNF, tumour necrosis factor.
Concentrations of SAA3 (μg ml−1), IL-1β, IL-6, TNF-α, CCL-2 and CXCL-10 (all pg ml−1) in
BALF from mice pretreated with S100A9 or S100A8/A9 for 2 h then LPS for 4 h. Data are
means± s.e.m., n=5 mice/group/treatment. *Po0.05, **Po0.01, ***Po0.001 compared with
the HBSS+LPS-treated group.
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control concentrations in BALF from LPS-challenged mice,
but concentrations were not significantly reduced by S100
pretreatment (Table 1). SAA3 is produced by airway epithelial
cells28 and we sought to validate its regulation by S100 proteins using
tracheal epithelial cells in vitro. Interestingly, S100A8/A9 significantly
increased SAA3 mRNA above controls (Po0.05) but S100A8 and
S100A9 had little effect. S100A9 and S100A8/A9 weakly suppressed
SAA3 mRNA induction by LPS in vitro whereas in keeping with
our earlier findings in vivo,11 S100A8 was significantly inhibitory
(Figure 4c).
Signalling pathways contributing to suppression of ALI by S100A9
and S100A8/A9
The MAPK pathway mediates signalling in response to LPS.
LPS inhalation reduced MAPK phosphatase (MKP; a key regulator of
this pathway) gene expression in lung whereas S100A9 and S100A8/A9
pretreatment tended to increase mRNA (Supplementary Table 2).
Western blotting confirmed decreased endogenous MKP-1 concentra-
tions in lung lysates following LPS inhalation. Unexpectedly, the S100
preparations reduced MKP-1 below levels found in LPS or control
samples (Figure 5a). When phosphorylation of p38 and Erk1/2 was
Figure 2 S100s reduce neutrophil influx and increase MC activation. Mice pretreated intranasally with S100A9 or S100A8/A9 for 2 h, challenged
intranasally with LPS then lungs examined 4 h later. (a) Neutrophil numbers in BALF; means± s.e.m., n=5 mice/group. *Po0.05, **Po0.01,
****Po0.0001 versus HBSS+LPS group. (b) Anti-S100A9 immunoreactivity indicates S100A9-positive myeloid cells and expression within the lung
parenchyma following LPS inhalation±S100. Sections representative of lungs from 5 mice per group; scale bars, 20 μm. (c and e) β-hex levels in BALF from
mice treated with (c) S100A9 or S100A8/A9 for 2 h and then LPS for 4 h or (e) S100A9 or S100A8/A9 alone; BALF collected at the times
indicated. Data are means± s.e.m., (c) n=5 mice per group, (e) n=4 mice per group; *Po0.05, **Po0.01, ****Po0.0001 versus (c) HBSS+LPS or
(e) HBSS-treated mice. (d) Ratio of degranulating MC number to total MC number in lung sections after LPS±S100A9 or S100A8/A9 pretreatment. Intact
and degranulating MCs in 6 sections from equivalent areas of lungs from each of 5 mice per group were manually counted by a blinded operator. Data are
means± s.e.m. of ratios of degranulating MC/total MC.
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compared, no significant changes in P-p38 were obvious (not shown);
S100A9 and S100A8/A9 pretreatments increased p-Erk1/2 above
amounts found in lungs from mice treated with LPS alone
(Figure 5a). p-MEK1/2 levels were similar with all treatments
(Figure 5a). Because changes may have occurred earlier than 4 h post
LPS challenge, lysates of lungs harvested 1 h post LPS challenge were also
examined, but no significant differences in MKP-1, or in phosphoryla-
tion levels of the MAPKs were found between groups (Figure 5b).
Figure 3 Comparison of S100A9 and S100A8/A9 pretreatments on genes induced by LPS. (a) Clustergram of mRNA expression of genes in lung tissue from
mice after administration of HBSS+PBS (control), HBSS+LPS, S100A9+LPS or S100A8/A9+LPS. Hierarchical clustering of the entire data set was
performed to provide a heat map with dendograms indicating co-regulated genes across groups; individual samples are shown, to validate variations in
reactivity within groups. (b and c) Volcano plot of mRNAs that were differentially regulated, with changes42.5-fold, and Po0.05 (blue line); plots arrange
fold differences along the x-axis and statistical significance along the y-axis. Results show mRNAs differentially regulated in lungs from (b) HBSS-pretreated
or (c) S100A8/A9-pretreated mice, then challenged with LPS, compared to S100A9-pretreated then LPS-challenged mice; n=5 mice per group.
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NF-κB mediates gene induction by LPS; S100A9 pretreatment did not
significantly alter NF-κB (p50) mRNA expression whereas S100A8/A9
significantly increased expression by LPS (Figure 6a). Formation of p50/
p50 homodimer can reduce LPS activation. Western blotting confirmed
significantly decreased p50 levels in LPS-treated lung. S100A9 pretreat-
ment prevented this decrease, and p50 levels were similar to those in
control extracts; S100A8/A9 exhibited a similar trend and both
preparations elevated p105 levels compared to LPS alone (Figure 6b).
Although S100A9 somewhat reduced IκBα levels 1 h post LPS challenge,
these were significantly increased after 4 h (Figure 6c). Silent information
regulator T1 (SIRT1) can also antagonise NF-κB signalling to suppress
inflammation.29 As expected, SIRT1 in lung extracts was significantly
decreased by LPS inhalation. S100A9 pretreatment prevented this
reduction and S100A8/A9 caused a similar trend (Figure 6d).
Figure 4 Effects of S100A9, S100A8/A9 and S100A8 on inflammation-associated gene expression induced by LPS in tracheal epithelial cells in vitro.
(a–c) Relative mRNA levels of (a) CCL-2, (b) CXCL-10 and (c) SAA3 4 h after incubation of tracheal epithelial cells with S100A9, S100A8/A9 or S100A8
(all 1 μM)±LPS (200 ng ml−1). β-actin was used as internal housekeeping gene. Data are means± s.e.m. of tracheal cell preparations from three different
mice; #Po0.05, ###Po0.001, ####Po0.0001 compared with LPS, *Po0.05, ***Po0.001, ****Po0.0001 compared with unstimulated cells.
Figure 5 Effects of S100A9 and S100A8/A9 on MKP-1 and MAPK phosphorylation. (a and b) Western blots corresponding to MKP-1, p-p38, p-Erk1/2,
p-MEK1/2 in lung lysates from mice treated with S100A9 or S100A8/A9 for 2 h and then LPS for (a) 4 h or (b) 1 h. A representative blot is shown; β-actin
was used for loading control; n=5 individual lung lysates/group in two independent analyses. Numbers indicate 1: HBSS+PBS, 2: HBSS+LPS, 3: S100A9
+LPS, 4: S100A8/A9+LPS.
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Suppressor of cytokine signalling 3 modulates ALI in response to
LPS30 and can negatively regulate signalling via STAT3. Here we
confirm elevated SOCS3 mRNA in lungs from mice challenged with
LPS, but unexpectedly, S100 pretreatment significantly restrained
SOCS3 induction, which was similar to that in controls (Figures 3b
and 6e). On the other hand, S100A9 and S100A8/A9 pretreatment
significantly increased STAT3 mRNA above that expressed in lungs
from mice only given LPS (Figure 6f) and Western blotting indicated
somewhat higher phosphorylated STAT3 in samples from mice
pretreated with the S100s (Figure 6g), suggesting activation.
Figure 6 Pathways contributing to suppression of ALI by S100A9 and S100A8/A9. (a, e and f) Relative mRNA levels of (a) NF-κB, (e) SOCS3 and (f) STAT3
in lung tissue from mice treated with S100A9 or S100A8/A9 for 2 h, then LPS for 4 h. Averages of HPRT, β-actin and GAPDH were used as internal
housekeeping genes (shown as HKG). Data are means± s.e.m., n=5 mice per group. *Po0.05, **Po0.01, ****Po0.001, ****Po0.0001 versus HBSS
+LPS group. (b–d and g) Western blots and quantitative signal intensities of densitometry of bands corresponding to (b) NF-κB, (c) IκBα, (d) SIRT1 and
(g) p-STAT3 in lung lysates from mice treated with S100A9 or S100A8/A9 for 2 h and then LPS for 1 h (IκBα) or 4 h (NF-κB, IκBα, SIRT1 and p-STAT3).
Representative blots are shown; densitometry shown as means± s.e.m. of bands relative to β-actin; n=5 individual lung lysates/group in two independent
analyses. *Po0.05, **Po0.01 versus HBSS+LPS group.
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DISCUSSION
The lung is constantly challenged with TLR ligands that trigger robust
reactions important in host defence. To limit tissue damage, the
epithelial innate and inflammatory response to pathogens is controlled
by numerous regulatory mechanisms,31 including hypo-responsiveness
to TLR activation.32 S100A8 and S100A8/A9 are reported TLR4 and
RAGE ligands8,13 although other receptors are implicated in S100A9
function.13,15,16 Proinflammatory properties of S100A9 and S100A8/
A9, either directly, or in combination with LPS are reported.2,4,8
S100A9 and S100A8/A9 can exhibit distinct extracellular functions,
and here we show both to be only weakly proinflammatory compared
to the intense induction of the TNF-α, IL-1β, IL-6, SAA3 and
chemokine genes typical of LPS (Supplementary Tables 1 and 2). In
lungs harvested 1 h post S100A9 or S100A8/A9 inhalation, TNF-α
mRNA increased ~ 2-fold; IL-1β was unaffected; IL-6 mRNA only
increased (some 4.5-fold) with S100A8/A9. These increases rapidly
declined and cytokine concentrations in BALF did not reflect a robust
TLR4-mediated response (Supplementary Tables 1 and 3). Different
functions of high and low doses of some S100 proteins are reported,33
but we found no significant differences in cytokine concentrations in
BALF following inhalation of 1, 10 or 25 μg S100A9 either with or
without LPS challenge (Supplementary Tables 3 and 4). Here we used
10 μg S100A9 to capture a comprehensive picture of inflammatory
gene expression in naïve mice over a time course.
S100A9 causes mild leucocyte influx in vivo,2 and following
intratracheal instillation into murine lung18 and we confirmed a mild
neutrophilia. In contrast to S100A8, which inhibits MC activation,11
S100A9 provoked activation 1–4 h post inhalation (Figure 2e) and
cytokines and chemokines released from preformed stores4 may
contribute to the leucocyte infiltration seen over 4–6 h. The rapid
induction of CXCL-1 and CXCL-2 mRNA 1 h post-inhalation of
S100A9 may contribute; responses to S100A8/A9 were weaker and
transient. CXCL-1 and CXCL-2 are neutrophil chemoattractants and
simultaneous transgenic overexpression of S100A8 and S100A9 in
murine hepatocytes promoted neutrophil mobilisation via CXCL-1
induction.34 Our results corroborate its likely contribution seen with
exogenous S100A9 and S100A8/A9 (Figure 1b). Monocytes were not
recruited in response to the S100s and the CCL-2 gene was unaffected.
In marked contrast to S100A8,11 S100A9 significantly increased
endogenous CXCL-10 mRNA 1–12 h post inhalation. Only BALF
from S100A9-treated mice collected 4 h post-treatment contained
significantly elevated CXCL-10, and although mRNA increased over
time, concentrations in BALF were low, suggesting that the amplitude
of CXCL-10 induction may be regulated by a post-transcriptional
mechanism, such as mRNA decay, that can influence chemokine
levels. CXCL-10 recruits lymphocytes and is strongly implicated in
autoimmune disorders characterised by elevated serum concentrations
of S100A8/A9 and S100A9. S100A9 is a proposed therapeutic target in
rheumatoid arthritis35 and inter-relationships between CXCL-10 and
S100A9 are worthy of further investigation. Interestingly, S100A8/A9
in particular, profoundly reduced basal mRNA levels of eotaxin-2
(CCL-24; Supplementary Table 1) suggesting that it may modulate
eosinophil recruitment in lung.
Protective mechanisms in innate immunity prevent excessive injury,
particularly at epithelial surfaces, and the S100s have protective
functions in antimicrobial3,20,21 and oxidative defence.1 Even though
S100A9 and S100A8/A9 are reported TLR4 agonists, we found no
fulminant expression of cytokine genes typical of an LPS-provoked
response. In keeping with this, inhalation of adenoviral S100A9 in
TLR4-deficient mice promoted lung pathology and inflammatory cell
infiltrates similar to those seen in wild-type mice, suggesting alternate
pathways.19 Furthermore, here we show that like S100A8,11 S100A8/
A9 and S100A9 pretreatment suppressed expression of key cytokine
and chemokine genes in response to LPS challenge 2 h later. It could
be argued that the S100s promote hypo-responsiveness, similar to
endotoxin tolerance,31,32 but the timing of S100 pretreatment and
LPS challenge renders this unlikely. Moreover, in the lung micro-
environment alveolar macrophages do not become tolerant to
endotoxin,36 repeated LPS inhalation does not reduce neutrophil
recruitment37 and, in contrast to our findings, neutrophil chemokines
CXCL-1 and CXCL-2 are not suppressed.38
S100A9 inhalation substantially suppressed the high induction of
chemokine genes by LPS, also reflected by CCL-2 and CXCL-10
concentrations in BALF. S100A9 also reduced TNF-α and
IL-6 mRNA/protein levels but not ΙL-1β. IL-1β processing and
secretion is dependent on activation of the NLRP3 inflammasome that
can be driven by SAA.39 S100A9 strongly reduced basal SAA3mRNA in
naïve lung (Supplementary Table 1), and the highly elevated SAA3 gene
expression induced by LPS in vivo, from 419-fold to 85-fold above
baseline (Supplementary Table 2) although there was no significant
change in protein concentrations in BALF; S100A8/A9 pretreatment
was not suppressive. Nevertheless, both preparations suppressed
neutrophil influx mediated by LPS in this study suggesting a more
generalised immunosuppression that may also affect SAA-mediated
responses. These results contrast markedly with S100A8, which, like
dexamethasone, strongly inhibited SAA induction by LPS in ALI.11
Little is known concerning IL-10 regulation in lung epithelial cells
and our combined studies suggest an important new pathway.
In marked contrast to S100A8, which directly stimulated high
IL-10 expression in the airway epithelium11 and in tracheal epithelial
cells in vitro, S100A8/A9 and S100A9 had no direct effect. S100A8 is
a redox-sensitive protein with a single highly reactive Cys residue.
Indeed, dithiol agents that restore glutathione levels in models of
airway hyper-responsiveness enhance IL-10 production in the lung
and attenuate disease and some consider IL-10 an ‘anti-inflammatory
anti-oxidant’.40 Although murine S100A9 has 3 Cys residues, these are
less reactive than Cys42 of S100A8
12 and although S100A8/A9 is not
disulphide-linked,12 the complex did not induce IL-10, suggesting
a novel structural mechanism that could modulate effects of S100A8
on redox signalling. Moreover, unlike S100A8, neither S100A8/A9 nor
S100A9 induced S100A8 mRNA. IL-10 is essential for S100A8
induction in murine macrophages by TLR agonists whereas S100A9
is not induced,3 and like IL-10, S100A8 is expressed in alveolar
macrophages of the M2-phenotype.11 Thus only S100A8 appears to
regulate an IL-10-dependent feedback to temper inflammation.
Signalling pathways contributing to S100 suppression of ALI are
likely to be complex. MKP-1 negatively regulates the MAPK pathway
mediating LPS-initiated signalling, although levels in lungs from
LPS-treated mice were significantly reduced by S100A9 and this may
facilitate a more sustained activation of the MAPK pathway, and
somewhat less effective immunosuppression than seen with S100A8.11
Although p38 and JNK are preferentially phosphorylated in response
to LPS, phosphorylation levels in lungs from S100-pretreated mice did
not change (not shown) and Erk phosphorylation was somewhat
elevated by S100A9. The lack of prominent changes suggested alternate
mechanisms.
S100A8 reduced gene induction of NF-κB and enhanced IκBα
expression, and we proposed these to contribute to suppression of
LPS-induced ALI.11 IκBα was also increased by S100A9 but at 4 h post
LPS inhalation, and may modulate intermediate response genes
induced by LPS. In addition, p50 subunit levels of NF-κB were
significantly elevated by S100A9 pretreatment, raising the possibility
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that the p50/p50 homodimer may be involved, as described for
inhibition of TNF-α production by resolvin-1-treated macrophages.41
SIRT1, an NAD+-dependent protein deacetylase sirtuin-1, suppresses
NF-κB signalling by deacetylating the p65 subunit. Agents such as
resveratrol that elevate SIRT1 expression in mice, significantly reduce
systemic levels of several cytokines (reviewed in ref. 29), and protect
against endotoxin shock and sepsis. SIRT1 − /− mice acquire sepsis-
induced ALI, and SIRT1 is implicated in suppression of NF-κB and
inflammasome activation to reduce inflammatory mediator
production.42 Here we show that S100A8/A9 and S100A9 restored
the basal SIRT1 levels that were reduced by LPS inhalation, and
propose a novel mechanism whereby regulation of SIRT1 by the
S100 proteins may contribute to their anti-inflammatory functions.
Although SOCS3 moderates LPS-induced inflammation, we found
significantly less SOCS3 mRNA induction in lungs from mice
pretreated with S100A8/A9 or S100A9. Notwithstanding, p-STAT3
was elevated in these samples. Elevated STAT3 activation contributes
to epithelial protection during ALI43 and may be involved in the
suppression by the S100 proteins. Analysis of the lung is complex and
characterisation at the cellular level may provide new insights. More
detailed investigation of downstream effects of the myeloid-derived
S100 proteins on these pathways, and their contributions to suppres-
sion of ALI, are warranted.
Here we demonstrate important functional differences of S100A8/
A9 and S100A9 that distinguish them from S100A8. Neither
influenced the S100A8/IL-10 induction pathway in the airways. On
the other hand, only S100A9 directly induced CXCL-10 that
may contribute to the neutrophilia seen with this protein. However
all S100 preparations reduced the strong induction of chemokine and
cytokine genes following LPS challenge although S100A8/A9 was least
effective (ref. 11 and Supplementary Table 2). In marked contrast to
S100A8, S100A9 or S100A8/A9 did not inhibit MC activation in vivo,
or effectively reduce SAA induction by LPS.11 Structural differences
within these proteins may contribute to functional diversity. For
example, the flexible extended C-terminal tail of S100A9 has a
potential ligand-binding domain implicated in neutrophil-
immobilising factor function.44 The hinge regions between the two
calcium-binding domains of S100A8 and S100A9 are structurally
divergent and differences in electrostatic potential and hydrophobicity
distribution around these may generate different binding affinities
and/or facilitate binding to different target proteins, producing specific
functions.45 Impacts of S100A8 and S100A9 would also depend on the
type expressed, and may be context- and concentration-dependent.
Nonetheless, results presented here demonstrate distinct and common
immunoregulatory functions for S100A8, S100A8/A9 and S100A9 in
the lung. We propose that their secretion by infiltrating myeloid cells,
and induction in macrophages and epithelial cells by particular
agonists, may contribute to normal lung homeostasis and protection
against excessive fulminant inflammation.
METHODS
Mice
Specific pathogen-free female BALB/c mice (7–9 weeks) from Australian
BioResources Ltd (Moss Vale, Australia) were used according to ethics
guidelines, with institutional approval of the Animal Care and Ethics
Committee of the University of New South Wales (reference number:
13/119A).
S100 preparations
Recombinant murine S100A8 and S100A946 expressed as GST-fusion proteins
in E. coli were treated with thrombin to remove GST, then purified to
homogeneity by sequential C4- and C18-reverse-phase high-performance liquid
chromatography, and reconstitution, validation of purity and mass of each
preparation was as described. Proteins differed from the native counterparts in
having an additional dipeptide, Gly-Ser at the N-terminus. Proteins were stored
in 45% acetonitrile, 0.1% trifluoroacetic acid at − 80 °C under argon.
Endotoxin levels were monitored and proteins only used if concentrations
were o10 pg/10 μg S100, tested by Limulus assay (Associates of Cape Cod). To
prepare the S100A8/A9 complex, equimolar amounts of S100A8 and S100A9 in
HBSS were incubated for 1 h at 4 °C under argon.
Endotoxin minimisation
Where possible, all work was performed in a pre-sterilised fume hood.
Incubations were in dedicated LPS-minimised incubators. All tissue culture
plates, tubes and so on were only used if stated to contain o2.0 endotoxin
units/item, otherwise were gamma-irradiated. Glassware for preparation of
media or buffers was treated with 0.1% NaOH, rinsed with sterile water
autoclaved, and baked at 250 °C for 30 min to vaporise remaining endotoxin.
Buffers that were not endotoxin free were Zetapore filtered. For high-
performance liquid chromatography preparation of recombinant S100s,
columns were pre-flushed with endotoxin-minimised buffers and fractions
collected into Nunc minisorb tubes (Nunc Roskilde Denmark) which do not
absorb these very hydrophobic proteins and when tested by us, do not contain
traces of endotoxin.
Assessment of effects on inflammation
To define direct effects of the S100s (10 μg/50 μl HBSS unless otherwise stated),
these were administered onto the nares and effects in lungs from mice sacrificed
1, 4, 6, 12 or 20 h post-inhalation as described.11 Inflammation induced by
LPS (E. coli, serotype 055:B5, Sigma-Aldrich, St. Louis, MO, USA) was with
10 μg/50 μl PBS administered intranasally. Intranasal S100s (10 μg/50 μl HBSS)
were given 2 h before LPS; control mice received equal volumes of vehicle
(HBSS+PBS). Mice were killed 4 h post LPS inhalation, or at 1 h where
indicated. Portions of right lung preserved in RNAlater (Thermo Fisher
Scientific, Waltham, MA, USA) were stored at 4 °C until RNA was extracted;
the remainder stored at − 80 °C to be used for protein extraction and analysis.
Left lungs were fixed in 10% neutral-buffered formalin.
Analysis of infiltrating cells and mast cell degranulation
Harvest of BALF and enumeration of leucocytes therein were as described.11
β-hex activity in BALF was used as a measure of MC degranulation as
described.11 Cell numbers, and MC that were degranulating, were manually
counted by a blinded operator.
RT-qPCR array
Total RNA preparation and PCR amplification was as described.11 Based on our
previous report on effects of S100A8 on ALI,11 46 genes mediating acute
inflammation, and 3 housekeeping genes, were chosen for this comparative
study (Supplementary Tables 1 and 2). Data analysis was performed essentially
as described using the web-based software package and Excel-based analysis
tool (SA Biosciences, Qiagen, Chadstone Centre, VIC, Australia).11 The HPRT,
β-actin and GAPDH were set as housekeeping genes (geometric mean) and all
Cp (cross point) values were set to a cut-off threshold of 37. Baseline levels of
genes in mice treated with vehicle (HBSS and PBS), and results for LPS alone,
and S100A9 or S100A8 were reported. Data files were lodged in the Gene
Expression Omnibus (accession no. GSE74129; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token= kvkhuoounnyhnkn&acc=GSE74129).
Immunohistochemistry
Serial sections of formalin-fixed, paraffin-embedded lung tissue (4 μm) were
stained with hematoxylin and eosin or anti-S100A8 or anti-S100A9 and imaged
as described.11 Rabbit anti-S100A8 IgG does not cross-react with S100A9;
anti-S100A9 IgG reacts with S100A9 and S100A8/A9 complex.
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Enzyme-linked immunosorbent assay
IL-1β, IL-4, IL-6, IL-10, TNF-α, CCL-2 and CXCL-10 enzyme-linked immu-
nosorbent assay kits were from R&D Systems (Minneapolis, MN, USA), and
SAA3 from MyBioSource (San Diego, CA, USA) and used according to
manufacturer’s instructions.
Western blotting
Lysates of lung homogenates (20 μg protein) were subjected to Western blotting
as described.11 The following antibodies were used: rabbit monoclonal
anti-phospho-MEK1/2 (Ser217/221, 1:1000 v/v), anti-phospho-p38 MAPK
(Thr180/Tyr182, 1:1000 v/v), anti-IκBα (1:1000 v/v) and NF-κB1 p105/p50
(1:1000 v/v), and rabbit polyclonal anti-MEK1/2 (1:1000 v/v), anti-phosho-
Erk1/2 MAPK (Thr202/Tyr204, 1:1000 v/v), anti-SIRT1 (1:1000 v/v), anti-
phospho-STAT3 (1:1000 v/v), anti-STAT3 (1:1000 v/v) (all from Cell Signaling
Technology, Danvers, MA, USA), and anti-MKP-1 (1:500 v/v, Santa Cruz
Biotechnology, Dallas, TX, USA). Anti-β-actin (1:500 v/v, rabbit polyclonal,
Thermo Fischer Scientific) was used to control for protein loading.
Mediator induction by S100A8 and S100A9 in tracheal epithelial
cells in vitro
Primary epithelial cells from excised trachea were established using a modified
method of Hiroshima et al.47 Tracheas cut into 0.5–1 mm fragments and
immobilised as explants on collagen 1-coated wells (5 μg cm− 2, collagen 1 in
0.1 M acetic acid) were cultured for 2 days at 37 °C in 5% CO2 in air in
Dulbecco’s modified eagle medium supplemented with 10% foetal bovine
serum, 100 units per ml penicillin, 100 μg ml− 1 streptomycin and 0.25 μg ml− 1
amphotericin B (all from Thermo), then for 20 days in keratinocyte-serum-free
medium (SFM) supplemented with 30 μg ml− 1 bovine pituitary extract,
0.2 ng ml− 1 epidermal growth factor and 100 μg ml− 1 kanamycin (all from
Thermo). After out-growth, cells were cultured until the second passage.
S100A9, S100A8/A9, S100A8 (all 1 μM) and/or LPS (200 ng ml− 1) and media
controls were incubated with cells for 4, 10 and 24 h, then cells harvested and
used to prepare RNA.
Statistical analysis
Lymphocyte and neutrophil numbers in time course experiments were analysed
using the Student’s t-test. Comparisons of mRNA levels between groups and
enzyme-linked immunosorbent assay results were analysed using a one-way
analysis of variance in conjunction with Bonferonni’s multiple comparisons
test. Gene expression data represent fold-changes of mRNA relative to controls,
of samples from lungs of minimum 4 mice in each group. P-values were
calculated using a Student’s t-test of the 2−ΔCp values for each gene between
two groups. Statistical significance was set at Po0.05. Hierarchical clustering of
the entire data set is presented as a clustergram. Volcano plots graph the log2 of
fold changes (ΔΔCt method, significance set at 2.5-fold) and -log10 of P-values
comparing S100A9 with S100A8/A9-treated mice (Student’s t-test, set at
Po0.05) for each gene. Clustergrams and volcano plots were generated by
web-based software (SA Biosciences). Statistical significance was set at Po0.05.
GraphPad Prism 6.00 software was used for data analysis.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
We thank Professor Mark Raftery for validating masses of S100A8 and S100A9
preparations by mass spectrometry. This research was supported by grants
#630647 and #1027189 from the National Health and Medical Research
Council of Australia.
1 Gomes LH, Raftery MJ, Yan WX, Goyette JD, Thomas PS, Geczy CL. S100A8 and
S100A9-oxidant scavengers in inflammation. Free Radic Biol Med 2013; 58:
170–186.
2 Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel
group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81:
28–37.
3 Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, Ross KF et al.
Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy
Agents Med Chem 2009; 8: 290–305.
4 Geczy CL, Chung YM, Hiroshima Y. Calgranulins may contribute vascular protection in
atherogenesis. Circ J 2014; 78: 271–280.
5 Hobbs JA, May R, Tanousis K, McNeill E, Mathies M, Gebhardt C et al. Myeloid cell
function in MRP-14 (S100A9) null mice. Mol Cell Biol 2003; 23: 2564–2576.
6 Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, Geczy CL et al. A null mutation in
the inflammation-associated S100 protein S100A8 causes early resorption of the
mouse embryo. J Immunol 1999; 163: 2209–2216.
7 Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M et al. Loss of S100A9
(MRP14) results in reduced interleukin-8-induced CD11b surface expression,
a polarized microfilament system, and diminished responsiveness to chemoattractants
in vitro. Mol Cell Biol 2003; 23: 1034–1043.
8 Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA et al. Mrp8 and
Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-
induced shock. Nat Med 2007; 13: 1042–1049.
9 Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate
endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation
end products. Circ Res 2008; 102: 1239–1246.
10 Zhao J, Endoh I, Hsu K, Tedla N, Endoh Y, Geczy CL. S100A8 modulates mast cell
function and suppresses eosinophil migration in acute asthma. Antioxid Redox Signal
2011; 14: 1589–1600.
11 Hiroshima Y, Hsu K, Tedla N, Chung YM, Chow S, Herbert C et al. S100A8 induces
IL-10 and protects against acute lung injury. J Immunol 2014; 192: 2800–2811.
12 Harrison CA, Raftery MJ, Walsh J, Alewood P, Iismaa SE, Thliveris S et al. Oxidation
regulates the inflammatory properties of the murine S100 protein S100A8. J Biol Chem
1999; 274: 8561–8569.
13 Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that
regulate function. Amino Acids 2011; 41: 821–842.
14 Pagano RL, Moraes NF, De Lorenzo BH, Coccuzzo Sampaio S, Mariano M, Giorgi R.
Inhibition of macrophage functions by the C-terminus of murine S100A9 is dependent
on B-1 cells. Mediat Inflamm 2014; 2014: 836491.
15 Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with
various binding partners. J Biochem 2016; 159: 481–490.
16 Arnold V, Cummings JS, Moreno-Nieves UY, Didier C, Gilbert A, Barré-Sinoussi F et al.
S100A9 protein is a novel ligand for the CD85j receptor and its interaction is
implicated in the control of HIV-1 replication by NK cells. Retrovirology 2013; 10:
122.
17 Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM et al. Inhibition of dendritic
cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is
regulated by S100A9 protein. J Exp Med 2008; 205: 2235–2249.
18 Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA et al. DAMP molecule
S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus
infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog 2014; 10:
e1003848.
19 Chen B, Miller AL, Rebelatto M, Brewah Y, Rowe DC, Clarke L et al. S100A9
induced inflammatory responses are mediated by distinct damage associated
molecular patterns (DAMP) receptors in vitro and in vivo. PLoS ONE 2015; 10:
e0115828.
20 Achouiti A, Vogl T, Van der Meer AJ, Stroo I, Florquin S, de Boer OJ et al. Myeloid-
related protein-14 deficiency promotes inflammation in staphylococcal pneumonia.
Eur Respir J 2015; 46: 464–473.
21 De Filippo K, Neill DR, Mathies M, Bangert M, McNeill E, Kadioglu A et al. A new
protective role for S100A9 in regulation of neutrophil recruitment during invasive
pneumococcal pneumonia. FASEB J 2014; 28: 3600–3608.
22 Fontaine M, Pachot A, Larue A, Mougin B, Landelle C, Venet F et al. Delayed increase
of S100A9 messenger RNA predicts hospital-acquired infection after septic shock. Crit
Care Med 2011; 39: 2684–2690.
23 Anthony D, Seow HJ, Uddin M, Thompson M, Dousha L, Vlahos R et al. Serum amyloid
A promotes lung neutrophilia by increasing IL-17 A levels in the mucosa and
gammadelta T cells. Am J Resp Crit Care Med 2013; 188: 179–186.
24 Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum
amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and
atherosclerosis. Redox Rep 2009; 14: 187–196.
25 Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S,
Schreurs BW et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human
osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum
2012; 64: 1477–1487.
26 Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory
cells in innate and adaptive immunity. Eur J Immunol 2010; 40: 1843–1851.
27 Wang JX, Kaieda S, Ameri S, Fishgal N, Dwyer D, Dellinger A et al. IL-33/ST2 axis
promotes mast cell survival via BCLXL. Proc Natl Acad Sci USA 2014; 111:
10281–10286.
28 Wilson TC, Bachurski CJ, Ikegami M, Jobe AH, Kallapur SG. Pulmonary and systemic
induction of SAA3 after ventilation and endotoxin in preterm lambs. Pediatr Res 2005;
58: 1204–1209.
29 Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk
between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders.
Cell Signal 2013; 25: 1939–1948.
Myeloid S100 proteins reduce lung inflammation
Y Hiroshima et al
471
Immunology and Cell Biology
30 Yan C, Ward PA, Wang X, Gao H. Myeloid depletion of SOCS3 enhances LPS-induced
acute lung injury through CCAAT/enhancer binding protein delta pathway. FASEB
J 2013; 27: 2967–2976.
31 Lang T, Mansell A. The negative regulation of Toll-like receptor and associated
pathways. Immunol Cell Biol 2007; 85: 425–434.
32 Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and
clinical significance. Trends Immunol 2009; 30: 475–487.
33 Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ et al. Functions of
S100 proteins. Curr Mol Med 2013; 13: 24–57.
34 Wiechert L, Nemeth J, Pusterla T, Bauer C, De Ponti A, Manthey S et al. Hepatocyte-
specific S100A8 and S100A9 transgene expression in mice causes Cxcl1 induction and
systemic neutrophil enrichment. Cell Commun Signal 2012; 10: 40.
35 Cesaro A, Anceriz N, Plante A, Page N, Tardif MR, Tessier PA. An inflammation loop
orchestrated by S100A9 and calprotectin is critical for development of arthritis. PLoS
ONE 2012; 7: e45478.
36 Philippart F, Fitting C, Cavaillon JM. Lung microenvironment contributes to the
resistance of alveolar macrophages to develop tolerance to endotoxin. Crit Care Med
2012; 40: 2987–2996.
37 Natarajan S, Kim J, Remick DG. Chronic pulmonary LPS tolerance induces selective
immunosuppression while maintaining the neutrophilic response. Shock 2010; 33:
162–169.
38 Natarajan S, Kim J, Remick DG. Acute pulmonary lipopolysaccharide tolerance
decreases TNF-α without reducing neutrophil recruitment. Immunol 2008; 181:
8402–8408.
39 Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE et al. Serum amyloid A
activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice.
J Immunol 2011; 187: 64–73.
40 Haddad JJ, Fahlman CS. Redox- and oxidant-mediated regulation of interleukin-10: an
anti-inflammatory, antioxidant cytokine? Biochem Biophys Res Commun 2002; 297:
163–176.
41 Lee HN, Kundu JK, Cha Y, Surh YJ. Resolvin D1 stimulates efferocytosis through
p50/p50-mediated suppression of tumor necrosis factor-alpha expression. J Cell Sci
2013; 126: 4037–4047.
42 Gao R, Ma Z, Hu Y, Chen J, Shetty S, Fu J. Sirt1 restrains lung inflammasome activation
in a murine model of sepsis. Am J Physiol Lung Cell Mol Physiol 2015; 308:
L847–L853.
43 Ikegami M, Falcone A, Whitsett JA. STAT-3 regulates surfactant phospholipid home-
ostasis in normal lung and during endotoxin-mediated lung injury. J Appl Physiol (1985)
2008; 104: 1753–1760.
44 Watt KW, Brightman IL, Goetzl EJ. Isolation of two polypeptides comprising the
neutrophil-immobilizing factor of human leucocytes. Immunology 1983; 48: 79–86.
45 Itou H, Yao M, Fujita I, Watanabe N, Suzuki M, Nishihira J et al. The crystal structure of
human MRP14 (S100A9), a Ca2+-dependent regulator protein in inflammatory process.
J Mol Biol 2002; 316: 265–276.
46 Raftery MJ, Collinson L, Geczy CL. Overexpression, oxidative refolding, and zinc binding
of recombinant forms of the murine S100 protein MRP14 (S100A9). Protein Expr Purif
1999; 15: 228–235.
47 Hiroshima Y, Bando M, Kataoka M, Inagaki Y, Herzberg MC, Ross KF et al. Regulation
of antimicrobial peptide expression in human gingival keratinocytes by interleukin-1α.
Arch Oral Biol 2011; 56: 761–767.
This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0 Interna-
tional License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in the credit line; if the material is not included
under the Creative Commons license, users will need to obtain
permission from the license holder to reproduce thematerial. To view
a copy of this license, visit http://creativecommons.org/licenses/by-
nc-sa/4.0/
r The Author(s) 2017
The Supplementary Information that accompanies this paper is available on the Immunology and Cell Biology website (http://www.nature.com/icb).
Myeloid S100 proteins reduce lung inflammation
Y Hiroshima et al
472
Immunology and Cell Biology
